Skip to content

Complication and Lung Function Impairment Prediction Using Perfusion and CT Air Trapping

Complication and Lung Function Impairment Prediction Using Perfusion and CT Air Trapping (CLIPPCAIR): Protocol for the Development and Validation of a Novel Algorithm for Post-resection Lung Function

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03885765
Acronym
CLIPPCAIR
Enrollment
160
Registered
2019-03-22
Start date
2020-09-21
Completion date
2025-04-18
Last updated
2025-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer

Brief summary

The primary objective of the CLIPPCAIR study is to construct and validate a new algorithm for predicting post-operative forced expiratory volume in 1 second (FEV1) values for lung resection candidates; this new model will be based on data derived from a thoracic CT scan with injection of contrast media.

Detailed description

Secondarily, the predictions made using traditional scintigraphic data will be compared with those from the new algorithm in a subset of high-risk patients, and cumulative contrast media and irradiation doses associated with imaging will be presented. How other measures of pulmonary function (e.g. transfer factor of the lung for carbon monoxide (TLCO)) and the presence/absence of operative complications might be predicted will also be investigated. Additionally, the potential links between (i) pre-surgical imaging data, (ii) post-surgical changes in respiratory function, and (iii) changes in health related quality of life will also be explored.

Interventions

DIAGNOSTIC_TESTPredictive data

The novel predictive data in this study includes 5 predefined variables derived from thoracic CT scans: (i) Expiratory to inspiratory ratio of mean lung density (MLDe/i), total; (ii) MLDe/i of the section to be excised / MLDe/i total; (iii) Percentage of emphysema according to voxel thresholding at -950 HU (PVOX-950), total; (iv) PVOX-950 for the section to be excised; (v) Iodine concentration \[I\] of the section to be excised / \[I\] total.

PROCEDURELung resection

Surgical resection will be characterised by type (pneumonectomy, bi-lobectomy, lobectomy, or lobectomy with anastomosis resection), whether or not lymph node dissection was performed, and whether or not the resection was atypical.

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient diagnosed with non-small cell lung cancer * Indication for pulmonary excision surgery * Patient requiring a more recent pre-surgical computed tomography scan (CT scan) * The patient has been correctly informed about the study and has signed the consent form * The patient is affiliated with or a beneficiary of the French single-payer social security programme (national health insurance)

Exclusion criteria

* Patient in an exclusion period determined by another protocol * Participation in another study that may affect the results of the present study (anti-cancer treatment studies are allowed) * Patient under legal or judicial protection * Contraindication to surgery or iodine injection * Pregnant or lactating women

Design outcomes

Primary

MeasureTime frame
Forced expiratory volume in 1 second (FEV1) from spirometry6 months
Correlation between predicted and real values for post-surgical FEV16 months

Secondary

MeasureTime frameDescription
Estimated post-operative FEV1 according segment counting (1)Baseline (day 0)FEV1post-seg-1 = FEV1pre-op x (1 - 0.0526 x N), where N is the number of segments to be excised
Estimated post-operative FEV1 according segment counting (2)Baseline (day 0)FEV1post-seg-2 = FEV1pre-op x \[(19 - a - b)/(19 - a)\], where a is the number of non-obstructed segments to be excised and b is the number of obstructed segments to be excised
Forced expiratory volume in 1 second (FEV1) from spirometryBaseline (day 0)
Forced vital capacity from spirometryBaseline (day 0)
FEV1/FVC from spirometryBaseline (day 0)
Total lung capacity from spirometryBaseline (day 0)lung volumes
Residual lung volume from spirometryBaseline (day 0)lung volumes
Estimated post-operative FEV1 (litres) according to scintigraphyBaseline (day 0)Estimated post-operative FEV1 (litres) deduced from the regional FEV1 distribution according to lung scintigraphy
Transfer factor of the lung for carbon monoxide (TLCO) from spirometryBaseline (day 0)
Maximum volume of oxygen utilized per unit time (VO2Max)Baseline (day 0)
EQ-5D-5L questionnaireBaseline (day 0)The 5 level EQ-5D version (EQ-5D-5L) is a standardized instrument for measuring generic health status. It results in a single index score describing a general health profile ranging from 0 to 1, as well as a visual analogue scale.
QLQ-C30 Version 3.0 questionnaireBaseline (day 0)The QLQ-C30 Version 3.0 (a quality of life questionnaire for lung cancer patients) results in three scale scores \[(i) level of function, (ii) global health status, and (iii) symptomatology / problems\] with higher scores (ranging from 0 to 100) representing a higher response level.
QLQ-LC13 questionnaireBaseline (day 0)The QLQ-LC13 provide an additional lung-cancer-specific symptom scale ranging from 0 to 100 with higher scores indicating worse symptomatology.
Number of participants with complications0 to 6 months
Functional residual lung capacity from spirometryBaseline (day 0)lung volumes
Estimated post-operative TLCO according to scintigraphyBaseline (day 0)estimated post-operative Transfer factor of the lung for carbon monoxide (TLCO) deduced from the regional TLCO distribution

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026